Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2018-04-09 (8 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: VERDUN-SUR-LE-DOUBS (71350), Saone-et-Loire
SELARL PHARMACIE DE VERDUN : revenue, balance sheet and financial ratios
SELARL PHARMACIE DE VERDUN is a French company
founded 8 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in VERDUN-SUR-LE-DOUBS (71350),
this company of category PME
shows in 2024 a revenue of 2.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE DE VERDUN (SIREN 838792984)
Indicator
2025
2024
2023
2021
2020
2019
Revenue
N/C
2 445 723 €
2 385 657 €
N/C
N/C
N/C
Net income
169 457 €
96 665 €
137 010 €
180 160 €
121 293 €
128 887 €
EBITDA
N/C
148 108 €
195 283 €
N/C
N/C
N/C
Net margin
N/C
4.0%
5.7%
N/C
N/C
N/C
Revenue and income statement
In 2025, SELARL PHARMACIE DE VERDUN generates positive net income of 169 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2019-2025: 129 k€ -> 169 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
169 457 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 8%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 80%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
7.821%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
79.993%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution SELARL PHARMACIE DE VERDUN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2023
2024
2025
Debt ratio
2.57
0.005
0.005
11.539
10.821
7.821
Financial autonomy
79.477
87.691
85.657
80.093
79.602
79.993
Repayment capacity
None
None
None
1.212
1.418
None
Cash flow / Revenue
None%
None%
None%
6.96%
5.334%
None%
Sector positioning
Debt ratio
7.822025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Excellent
In 2025, the debt ratio of SELARL PHARMACIE DE VERDUN (7.82) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
79.99%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Excellent+6 pts over 3 years
In 2025, the financial autonomy of SELARL PHARMACIE DE VERDUN (80.0%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
1.42 years2024
2023
2024
Q1: 0.52 years
Med: 3.19 years
Q3: 7.6 years
Good+6 pts over 2 years
In 2024, the repayment capacity of SELARL PHARMACIE DE VERDUN (1.42) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 234.85. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
234.848
Liquidity indicators evolution SELARL PHARMACIE DE VERDUN
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2019
2020
2021
2023
2024
2025
Liquidity ratio
198.303
231.234
236.29
286.96
263.82
234.848
Interest coverage
None
None
None
0.478
5.674
None
Sector positioning
Liquidity ratio
234.852025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Good-8 pts over 3 years
In 2025, the liquidity ratio of SELARL PHARMACIE DE VERDUN (234.85) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
5.67x2024
2023
2024
Q1: 0.0x
Med: 2.35x
Q3: 7.73x
Good+39 pts over 2 years
In 2024, the interest coverage of SELARL PHARMACIE DE VERDUN (5.7x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 225 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 732 days. Excellent situation: suppliers finance 507 days of the operating cycle (retail model).
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
225 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
732 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE DE VERDUN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2023
2024
2025
Operating WCR
0 €
0 €
0 €
419 136 €
335 578 €
0 €
Inventory turnover (days)
0
0
0
48
45
0
Customer payment term (days)
0
0
0
12
6
225
Supplier payment term (days)
0
0
0
35
39
732
Positioning of SELARL PHARMACIE DE VERDUN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE DE VERDUN is estimated at
2 691 844 €
(range 1 826 698€ - 4 223 874€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1826k€2691k€4223k€
2 691 844 €Range: 1 826 698€ - 4 223 874€
NAF 5 année 2025
Valuation method used
Net Income Multiple
169 457 €
×
15.9x
=2 691 845 €
Range: 1 826 698€ - 4 223 875€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE DE VERDUN with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE DE VERDUN
What is the revenue of SELARL PHARMACIE DE VERDUN ?
The revenue of SELARL PHARMACIE DE VERDUN in 2024 is 2.4 M€.
Is SELARL PHARMACIE DE VERDUN profitable?
Yes, SELARL PHARMACIE DE VERDUN generated a net profit of 169 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE DE VERDUN ?
The headquarters of SELARL PHARMACIE DE VERDUN is located in VERDUN-SUR-LE-DOUBS (71350), in the department Saone-et-Loire.
Where to find the tax return of SELARL PHARMACIE DE VERDUN ?
The tax return of SELARL PHARMACIE DE VERDUN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE DE VERDUN operate?
SELARL PHARMACIE DE VERDUN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart